Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018045058 - DRUG DELIVERY COMPOSITIONS AND USES THEREOF


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2017/049424 D0504 70120
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
30 August 2017 30 August 2016
Applicant
DANA-FARBER CANCER INSTITUTE, INC
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 9/06 (2006.01)i; A61K 9/00 (2006.01)i; A61K 47/36 (2006.01)i; A61K 38/17 (2006.01)i; A61K 38/19 (2006.01)i; A61K 39/395 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2016119308 A1 (UNION HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE A) 04 August 2016 (2016-08-04)
1,3,6,41,46,47,50,52,53,75-77,79-81,90-92,98-101,133,135,137
Y
claims 1, 2, 7
1-144
examples 1-2
(2)
X
XU KEMING ET AL, "Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-[alpha]2a for liver cancer therapy", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL,Vol. 166, No. 3, 14 January 2013 (2013-01-14), page 203-210,
XP028994979
4,46-49,67,70,98-101,103,104,134,136
Y
abstract
1-144
page 204, column 2, paragraphs 1, 2
(3)
X
HORI Y ET AL, "Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy", December 2009 (2009-12), Vol. 30, No. 35, page 6757-6767,
XP026693729
[retrieved on  2009-09-19]
1,2,4,13,46,50,55-58,67,69,98-101,103,104,133,134,136
Y
abstract
1-144
(4)
X
US 2007213393 A1 (HUNTER WILLIAM L [CA] ET AL) 13 September 2007 (2007-09-13)
1,46-49,98-101,135
Y
examples 5, 6
1-144
(5)
X
US 9364545 B2 (UNIV TAIPEI MEDICAL [TW]) 14 June 2016 (2016-06-14)
1,46-49,98,100,101,135
Y
example 1
1-144
(6)
Y
WO 2016123573 A1 (HARVARD COLLEGE [US]) 04 August 2016 (2016-08-04)
1-144
claims 1, 10-21, 24-26, 29-42
example 1
(7)
Y
HORI Y ET AL, "Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors", May 2009 (2009-05), Vol. 5, No. 4, page 969-982,
XP026051872
[retrieved on  2009-04-15]
1-144
abstract
(8)
Y
WO 2011078990 A1 (BENAROYA RES INST AT VIRGINIA MASON [US]; BOLLYKY PAUL [US]; NEPOM GER) 30 June 2011 (2011-06-30)
1-144
claims 1, 8, 9, 11, 13-15
(9)
Y
PEATTIE R A ET AL, "Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB,Vol. 25, No. 14, June 2004 (2004-06), page 2789-2798,
XP004489027
1-144
abstract
(10)
Y
PEATTIE ROBERT A, "Release of growth factors, cytokines and therapeutic molecules by hyaluronan-based hydrogels", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, NL,Vol. 13, No. 7, 31 May 2012 (2012-05-31), page 1299-1305,
XP009502102
1-144
the whole document
(11)
Y
WO 2016004213 A2 (VICUS THERAPEUTICS LLC [US]) 07 January 2016 (2016-01-07)
1-144
claims 1, 4, 6, 7, 12, 15
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2016119308 A1
04 August 2016
CN 105983097 A
WO 2016119308 A1
05 October 2016
04 August 2016
US 2007213393 A1
13 September 2007
US 2003157161 A1
US 2007213393 A1
21 August 2003
13 September 2007
US 9364545 B2
14 June 2016
TW 201609146 A
US 2015366975 A1
16 March 2016
24 December 2015
WO 2016123573 A1
04 August 2016
EP 3250250 A1
WO 2016123573 A1
06 December 2017
04 August 2016
WO 2011078990 A1
30 June 2011
NONE
WO 2016004213 A2
07 January 2016
EP 3164157 A2
US 2017136127 A1
WO 2016004213 A2
10 May 2017
18 May 2017
07 January 2016
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
11 December 2017
Date of mailing of the international search report:
21 December 2017
Authorized officer:
Peris Antoli, Berta
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E